<PAGE>

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                   Form 10-KSB


[X]  ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
     OF 1934

              For the fiscal year ended        December 31, 2001
                                          ---------------------------------

[  ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
     ACT OF 1934

     For the transition period from _______________________ to _____________

                        Commission file number 000-27339
                            ------------------------

                                 BEPARIKO BIOCOM
                   ------------------------------------------
                 (Name of small business issuer in its charter)


         NEVADA                                        88-0426887
-------------------------                  -----------------------------------
(State or other jurisdiction              (I.R.S. Employer Identification No.)
of incorporation or organization)


      One Belmont Avenue, Suite 417
        Bala Cynwyd, Pennsylvania                             19004
----------------------------------------               -----------------------
(Address of principal executive offices)                     (Zip Code)

Issuer's telephone number:     (610) 660-5906
                           -------------------------------

Securities registered under Section 12(b) of the Exchange Act:

       Title of each class            Name of each exchange on which registered

              None                                 Not Applicable
-----------------------------------   -----------------------------------------

Securities registered under Section 12(g) of the Exchange Act:

                     Common Stock $0.001 par value per share
-------------------------------------------------------------------------------
                                (Title of class)

Check whether the issuer (1) filed all reports required to be filed by Section
13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter
period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days. [X] Yes [ ] No

<PAGE>


Check if there is no disclosure of delinquent filers in response to Item 405 of
Regulation S-B is not contained in this form, and no disclosure will be
contained, to the best of registrant's knowledge, in definitive proxy or
information statements incorporated by reference in Part III of this Form 10-KSB
or any amendment to this Form 10-KSB. [ ]

State issuer's revenues for its most recent fiscal year:       $0.00
                                                               -----

State the aggregate market value of the voting and non-voting common equity held
by non-affiliates based on the last sale price for the Registrant's common
stock: As at April 3 2002 the aggregate market value of the Company's Common
Stock (based upon the last reported sale price on the National Association of
Securities Dealers OTC Bulletin Board), excluding outstanding shares
beneficially owned by affiliates, was approximately $8,337,500.00, being $1.45
per share.

State the number of shares outstanding of each of the issuer's classes of common
equity, as of the latest practicable date. As at April 10 2002, there were
5,750,000 shares of Common stock issued and outstanding.

                       DOCUMENTS INCORPORATED BY REFERENCE

None

Transitional Small Business Disclosure Format (Check one): Yes     ; No   X
                                                              -----     -----

                                     -ii-

<PAGE>


                                TABLE OF CONTENTS


<TABLE>
<CAPTION>
                                                       PART I


<S>                                                                                                              <C>
   ITEM 1 DESCRIPTION OF BUSINESS.................................................................................4

   ITEM 2 DESCRIPTION OF PROPERTY.................................................................................9

   ITEM 3 LEGAL PROCEEDINGS......................................................................................10

   ITEM 4 SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS....................................................10

                                                       PART II


   ITEM 5 MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS...............................................10

   ITEM 6 MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION..............................................12

   ITEM 7 FINANCIAL STATEMENTS...................................................................................17

   ITEM 8 CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE...................17

                                                      PART III


   ITEM 9 DIRECTORS, EXECUTIVE OFFICERS, PROMOTERS AND CONTROL PERSONS; COMPLIANCE WITH SECTION 16(A) OF THE
   EXCHANGE ACT..................................................................................................17

   ITEM 10 EXECUTIVE COMPENSATION................................................................................18

   ITEM 11 SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT........................................18

   ITEM 12 CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS........................................................19

   ITEM 13 EXHIBITS AND REPORTS ON FORM 8-K......................................................................19
</TABLE>

NOTE REGARDING PROJECTIONS AND FORWARD LOOKING STATEMENTS

Except for statements that report the Company's historical results and
disclosures of historical fact, certain information contained herein constitutes
"forward-looking statements." Words or phrases "will likely result", "areP
expected to", "will continue", "is anticipated", "anticipate", "estimate",
"intend", "project or projected", or similar expressions are intended to
identify "forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Such forward-looking statements
involve known and unknown risks, uncertainties and other factors which may cause
the actual results or achievements of the Company to be materially different
from any future results or achievements of the Company expressed or implied by
such forward-looking statements. Such factors include among other things, the
Company's history of losses, lack of revenues and stage in the development of
its business, the Company's lack of working capital and uncertainties related to
its ability to continue as a going concern. Please see generally "Part I. Item
1. - Risk Factors" below.

Additional information and factors that could cause actual results to differ
materially from those in the forward-looking statements are set forth in this
Form 10-KSB for the fiscal year ended December 31, 2001, including specifically
those sections entitled "Risk Factors" and "Management's Discussion and Analysis
or Plan of Operation." The Company hereby cautions shareholders, prospective
investors in the Company, and other readers to not place undue reliance on these
forward-looking statements, which can only address known events as of the date
of this Report.


                                    -iii-
<PAGE>




                                     PART I

Item 1 Description of Business

BEPARIKO BIOCOM ("Bepariko or the "Company") is a Nevada corporation formed on
April 2, 1997. The Company's offices are located at One Belmont Avenue, Suite
417, Bala Cynwyd, Pennsylvania 19004; (610) 660-5906. The Company operates on
the calendar fiscal year. Currently, the Company has only one employee, its sole
director and officer, and he will be the only employee for the foreseeable
future. The Company has no subsidiaries at this time.

The Company holds worldwide patent rights for electronic multiple fingerprint
recognition procedures and systems. The patent license granted Bepariko, covers
the digitization of all ten of the users fingerprints into a database with a
corresponding smart card also containing all the users fingerprints. The patent
is both objective and subjective. Objectively the patent application uses all
ten of the users' fingerprints, subjectively the user may select which fingers
he wishes to use for their personal identification code, and they may
selectively substitute other fingers for his access security code.

The details of a German patent and its inventor were brought to the attention of
Mr. Lewis Eslick, the founder and a former director and officer of the Company,
by Dipl.-Kfm. Peter Riedel, an accountant and business advisor residing in
Germany. Mr. Riedel was one of the backers that financially supported the work
necessary to obtain the patent. Following negotiations with the patent owner, it
was agreed that Mr. Eslick or his nominated company would be granted an
exclusive licensing agreement for the use of the patent.

The patent was initially registered with the Federal Republic of German under
patent number 43 22 445, and the patent was granted on June 7, 1993. The patent
was registered filed for and granted throughout the nations of the European
Economic Community. The registration of the patent in the United States and most
industrialized nations of the world followed.

Ms. Eslick elected to file Bepariko BioCom, a Nevada corporation, so that it
could be granted the exclusive licensing agreement. A set dollar amount was not
determined regarding the value of the licensing agreement.

Mr. Alfons Behnke, the patent owner, sent Mr. Tino Di Pana to the United States
with full power of attorney to grant the exclusive licensing agreement to
Bepariko BioCom, Nevada. On April 11, 1997 our Company was granted, in
perpetuity, the unrestricted exclusive right to use of all of the rights and
privileges granted within patent 43 22 445 given by the Federal Republic of
Germany. It was verbally agreed that a percentage of any net profits earned by
our Company, through the use of the patent, would be paid to the patent owner.
This percentage would be determined on a contract by contract basis and would
not exceed 10% as a maximum cost to Bepariko.

The Company was organized to be an international corporation; a business to be
owned by the public at large and operated in accordance with the directives of
the board of directors. Bepariko's management is committed to continually
maintain, develop, and enhance its security systems to meet the changing
processing needs of the industry. In developing its service products, Bepariko
will be stressing responsiveness to the needs of its clients through client
contact and customer service.
<PAGE>

Bepariko's multi-fingerprint access coded systems provide absolute security in
many applications. Bepariko provides an economically high quality business
solution to lowering costs, preventing fraudulent uses and providing absolute
security to its cardholders. Building new database systems is not required for
these applications. Cooperation, level-headedness and the conviction that
Bepariko's multi-fingerprint access codes will lower and then contain losses in
the fields of theft and fraud for its cardholders.

In March 2001, Bepariko announced that it had entered into a definitive
agreement with the shareholders of Global Genomics Capital, Inc. ("GGC"), a
California company, to acquire all of the issued and outstanding shares of GGC
in exchange for the issuance by the Company of approximately 9.1 million shares
in its capital. In October 2001, the Company and the shareholders of GGC
terminated the Acquisition Agreement

Subsequent to December 31, 2001, the Company announced that it had executed a
letter of intent to acquire First Responder Group, Inc. ("First Responder"), a
New York based company involved in the provision of goods and services used to
educate prepare and protect consumers and health professionals in the area of
domestic preparedness against terrorism.

The acquisition of First Responder is subject to a number of conditions
precedent including: the completion by the Company, of due diligence and a
financing by the Company and the execution of a definitive merger agreement
between the Company and First Responder.

Narrative Description of the Business

The Company holds worldwide patent rights for electronic multiple fingerprint
recognition procedures and systems. The patent license granted Bepariko, covers
the digitization of all ten of the users fingerprints into a database with a
corresponding smart card also containing all the users fingerprints. The patent
is both objective and subjective. Objectively the patent application uses all
ten of the users' fingerprints, subjectively the user may select which fingers
he wishes to use for their personal identification code, and they may
selectively substitute other fingers for his access security code.

The security for card users is accomplished by digitizing all ten of the users
fingerprints encoded onto a database with the key fingerprint stored on the
users corresponding smart card. The key fingerprint gains access to the doorway
of the database, which than allows the card user to select his personal
identification coded fingerprints for absolute identification. These
fingerprints may also be stored in a remote access control database. To use the
card, the user must pass his card through a normal magnetic card reader and
place his personal identification coded fingers onto the fingerprint reader.
When the personal identification coded fingers and the database match those of
the user, access is granted. If there is no match, access is denied. The
following are some of the most apparent ways that the patent could be applied:

Consumer Credit Card Companies, suffer monumental annual losses due to stolen,
lost and fraudulent credit cards. The multi- fingerprint access codes provide
absolute security for these credit cards and the issuing Companies.

Hotel and Hotel/Casino applications, the database for the system is kept on the
premises with the capabilities to integrate with other database applications
worldwide through existing communication satellites. The guest's fingerprints
are recorded at the registration desk upon his arrival. Thereafter, the guest
will access his room or he can make purchases by the use of his fingerprint in a
fingerprint reader. For casino applications a fingerprint reader attached to
the gaming machines and gaming tables allows the guest to participate in gaming
activities and charge those activities to the credit card he used upon his
arrival.

                                      -5-
<PAGE>

Bank ATM cards currently require access numbers or pin numbers to access the
customers account. The multi-fingerprint access codes provide absolute security
for the ATM card user and the banks issuing the cards. The authorized user
encodes his fingerprints onto the ATM card with a duplicate into the databases
of the banks. Upon the electronic match of the fingerprints the user accesses
his account. If there is no match, entry to the account is denied.

Identification Cards for medical insurance coverage's currently have no
security. According to the New England Journal of Medicine and the US
Congressional Committee, March 1995 there is $75 to $80 billion estimated as
fraudulent charges in Medical Insurance Coverage's annually. A multi-fingerprint
access coded medical identification card would provide absolute security against
fraudulent use in this industry.

Computer access through the use of the multi-fingerprint access codes would
provide absolute security in this industry. This could also be adapted to
Internet credit card purchases without fear of misuse of the credit card.

Remote and access controls governed through the use multi-fingerprint access
codes provides absolute security in these applications.

Military requirements provide the possibility for various uses of the
multi-fingerprint access coded systems

Automobile locking systems and automobile anti-theft systems can incorporate the
multi-fingerprint access codes through the onboard computer already on the
automobile.

Risk Factors

Our business is subject to a number of risks that are generally associated with
start-up companies in the development stage of their business. These risks could
cause our actual results to differ materially from the results we project and
any forward-looking statement we make in this Report on Form 10-KSB. Below is a
description of some of the risks that we anticipate will be associated with our
business and with an investment in our company. We also encourage our
shareholders to familiarize themselves with that portion of our registration
statement on Form SB-2 entitled "Risk Factors."

Risks Related To Our Business and Operations

We are an under-funded start-up business and we have no significant history of
operations.

We were only recently formed and we do not have any revenues from operations. As
of December 31, 2001, we had cash or cash equivalents on hand of $47 and working
capital of $71,395. We had accounts payable and accrued expenses in the amount
of $178,652 and notes payable of $318,000. We were initially funded by the sale
of common shares in our registered offering and through promissory notes in an
aggregate face amount of $310,000. Our auditors have expressed doubt regarding
our ability to continue as a going concern. We are a development stage company
and we are undercapitalized.

                                      -6-
<PAGE>

If we are unable to establish a revenue stream or secure other alternative
sources of financing, our ability to continue as a going concern is doubtful. As
the costs associated with maintaining our corporate and regulatory requirements
continue to increase, it will be difficult for us to predict our budget
requirements. We will only be able to continue operating if we are able to
establish revenues.

There can be no assurance that we will successfully raise the financing required
to fund our operation or continue as a going concern. If we are unable to raise
sufficient financing to fund our business strategy, you may lose your entire
investment in our company.

There can be no assurance that a business model such as ours will prove to be
viable or that our budget will be sustainable on that account.

We have incurred losses since our inception and we expect losses to continue for
the foreseeable future.

We are in the extreme early stages of development and could fail before
implementing our business strategy. We are a "start-up" venture that will incur
net losses for the foreseeable future. Since our inception through the fiscal
year ended December 31, 2001, we have incurred net losses of $284,679. Our net
loss for the fiscal twelve month period ending December 31, 2001 was $243,505.
We will incur additional expenses and losses before becoming profitable, if we
ever become profitable. We were recently formed, and we have not earned any
revenues. We have no meaningful historical financial data upon which to base our
planned operating expenses or losses. As a result of our limited operating
history, it is difficult to accurately forecast our potential revenue. In order
to become profitable, we must:

- execute on our business model;

- access additional capital when required; and - attract and retain key
personnel.

Our financial statements have been prepared on a going concern basis, which
presumes the realization of assets and the settlement of liabilities in the
normal course of operations. The application of the going concern principle is
dependent upon the Company achieving profitable operations to generate
sufficient cash flows to fund continued operations, or, in the absence of
adequate cash flows from operations, obtaining additional financing. If the
Company is unable to achieve profitable operations or obtain additional
financing, we may be required to reduce or to limit operations, or cease
operations altogether. The auditors' report on the December 31, 2001
consolidated financial statements contains an explanatory paragraph that states
that the Company has suffered losses and negative cash flows from operations
that raise substantial doubt about the Company's ability to continue as a going
concern. The financial statements do not include any adjustments that might
result from the outcome of this uncertainty.

We cannot be certain that our business model will be successful or that it will
successfully address these and other challenges, risks and uncertainties. If we
fail to successfully meet these challenges, we will likely never become
profitable.

We cannot promise that we will be able to comply with any existing or future
laws, regulations, interpretations or applications without incurring significant
costs or adjusting our business model.

                                      -7-
<PAGE>

We will need additional capital to continue to operate our business.

We have not yet achieved profitable operations or secured a long-term source of
revenue. We do not have sufficient cash and cash equivalents on hand to conduct
our operations through the first quarter of 2002, and are substantially
dependent on continued funding from our President and CEO to continue
operations. We will need to obtain additional financing to support our
operations for the duration of 2002.

If we successfully raise additional funds through the issuance of debt, we will
be required to service that debt and are likely to become subject to restrictive
covenants and other restrictions contained in the instruments governing that
debt, which may limit our operational flexibility. If we raise additional funds
through the issuance of equity securities, then those securities may have
rights, preferences or privileges senior to the rights of holders of our Common
Stock, and holders of our Common Stock will experience dilution.

We cannot be certain that such additional financing will be available to us on
favorable terms when required, or at all. If we cannot raise funds in a timely
manner on acceptable terms, we may not be able to promote our brand, develop or
enhance our products and services, take advantage of future opportunities or
respond to competitive pressures or unexpected requirements, and we may be
required to reduce or limit operations.

Investment Related Risks

Our shares are considered penny stock and are subject to the penny stock rules,
which may adversely affect your ability to sell your shares

Investors may face significant restrictions on the resale of our Common Stock
due to federal penny stock regulations.

In addition, the Securities and Exchange Commission has adopted a number of
rules to regulate "penny stocks." These rules include Rules 3a51-1, 15g-1,
15g-2, 15g-3, 15g-4, 15g-5, 15g-6 and 15g-7 under the Securities and Exchange
Act of 1934, as amended. Because our Common Stock may constitute "penny stock"
within the meaning of the rules, the rules would apply to us and any of our
shares of Common Stock. The rules may further affect the ability of owners of
our common shares to sell their securities in any market that may develop for
them. There may be a limited market for penny stocks, due to the regulatory
burdens on broker-dealers. The market among dealers may not be active. Investors
in penny stock often are unable to sell stock back to the dealer that sold them
the stock. The mark ups or commissions charged by the broker-dealers may be
greater than any profit a seller may make. Because of large dealer spreads,
investors may be unable to sell the stock immediately back to the dealer at the
same price the dealer sold the stock to the investor. In some cases, the stock
may fall quickly in value. Investors may be unable to reap any profit from any
sale of the stock, if they can sell it at all.

Shareholders should be aware that, according to the Securities and Exchange
Commission Release No. 34-29093, the market for penny stocks has suffered in
recent years from patterns of fraud and abuse. These patterns include:

- control of the market for the security by one or a few broker-dealers that are
often related to the promoter or issuer;

                                      -8-
<PAGE>

- manipulation of prices through prearranged matching of purchases and sales and
false and misleading press releases;

- "boiler room" practices involving high-pressure sales tactics and unrealistic
price projections by inexperienced sales persons;

- excessive and undisclosed bid-ask differentials and markups by selling
broker-dealers; and

- the wholesale dumping of the same securities by promoters and broker-dealers
after prices have been manipulated to a desired level, along with the inevitable
collapse of those prices with consequent investor losses.

Substantial sales of our Common Stock could cause our stock price to fall.

If our stockholders sell substantial amounts of our Common Stock, the market
price of our common stock could decline. As of the date of this Report, we have
outstanding 5,750,000 shares of Common Stock. All of the shares of our Common
Stock outstanding are freely tradeable in the public market.

We have not declared dividends and may never declare dividends, which may affect
the value of your shares

We have never declared or paid any dividends on our Common Stock and do not
expect to pay any dividends in the near future.

You should not place undue reliance on forward-looking statements as they are
inherently uncertain.

This Annual Report on Form 10-KSB contains forward-looking statements that
involve risks and uncertainties which you should not place undue reliance upon.
We use words such as "anticipates," "believes," "plans," "expects," "future,"
"intends" and similar expressions to identify these forward-looking statements.
Prospective investors should not place undue reliance on forward-looking
statements. Our actual results could differ materially from those anticipated in
these forward-looking statements for many reasons, including the risks faced by
our company described in "Risk Factors" and elsewhere in this Report.

Item 2 Description of Property.

The Company does not own or lease any real or personal property. The Company
currently maintains an administrative office without charge out of space donated
by the Company's President and sole director, at One Belmont Avenue, Suite 417,
Bala Cynwyd, Pennsylvania 19004.

The Company has no policy with respect to:

1.       investments in real estate or interest in real estate;

2.       investments in real estate mortgages; or

3.       securities of or interests in persons primarily engaged in
         real estate activities.

                                      -9-
<PAGE>

Item 3 Legal Proceedings.

Bepariko is not currently a party to any material legal proceeding, and was not
a party to any legal proceeding during the fiscal year ended December 31, 2001.
Management of the Company is currently not aware of any legal proceedings
proposed to be initiated against the Company. However, from time to time, the
Company may become subject to claims and litigation generally associated with
any business venture.

Item 4 Submission of Matters to a Vote of Security Holders.

No matters were submitted to a vote of the security holders during fiscal
quarter ended December 31, 2001.

                                    PART II

Item 5 Market for Common Equity and Related Stockholder Matters.

                               Market Information

Our Common Stock is currently quoted on the National Association of Securities
Dealers OTC Bulletin Board (the "OTC Bulletin Board") under the symbol "BPKO".
The Common Stock has been posted for trading on the OTC Bulletin Board since May
24, 2000, however the Common Stock has only traded since January 24, 2001. Stock
and Company information may also be obtained via the Internet. The bid
quotations set forth below, reflect inter-dealer prices, without retail mark-up,
mark-down or commission and may not reflect actual transactions.

--------------------------------------------------------------------------------
Period ended                       High                         Low
--------------------------------------------------------------------------------
January 31, 2001                   $3.875                       $0.25
--------------------------------------------------------------------------------
February 28, 2001                  $4.875                       $3.00
--------------------------------------------------------------------------------
March 31, 2001                     $5.125                       $3.75
--------------------------------------------------------------------------------
April 30, 2001                     $5.25                        $5.00
--------------------------------------------------------------------------------
May 31, 2001                       $5.00                        $4.80
--------------------------------------------------------------------------------
June 30, 2001                      $4.80                        $2.85
--------------------------------------------------------------------------------
July 31, 2001                      $2.85                        $2.85
--------------------------------------------------------------------------------
August 31, 2001                    $2.85                        $1.55
--------------------------------------------------------------------------------
September 30, 2001                 $1.50                        $0.55
--------------------------------------------------------------------------------
October 31, 2001                   $1.65                        $0.60
--------------------------------------------------------------------------------
November 30, 2001                  $3.00                        $1.75
--------------------------------------------------------------------------------
December 31, 2001                  $2.50                        $2.00
--------------------------------------------------------------------------------

                                      -10-
<PAGE>

On April 3, 2002, the last reported sales price of our Common Stock, as reported
by the OTCBB, was $1.45 per share. Other than as described above, the Company's
Common Stock is not and has not been listed or quoted on any other exchange or
quotation system.

                                  Shareholders

The Company's authorized capital stock consists of 100,000,000 shares of Common
Stock, par value $.001 per share, and 10,000,000 shares of preferred stock, par
value $.0001 per share ("Preferred Stock"). As of December 31, 2001, the Company
believes there are approximately 58 shareholders of record. A number of these
shares are held in "street" name and may, therefore, be held by several
beneficial owners. As of April 10, 2002, the Company believes there are
approximately there are 56 holders of Company's Common Stock. A number of these
shares are held in "street" name and may, therefore, be held by several
beneficial owners.

                                    Dividends

Bepariko has not paid any dividends on its Common Stock since its inception, and
our board of directors currently intends to retain all earnings for use in the
business for the foreseeable future. Any future payment of dividends will depend
upon our results of operations, financial condition, cash requirements and other
factors deemed relevant by our board of directors.

                     Recent Sales Of Unregistered Securities

As previously disclosed in the Company's report on 10-QSB for the period ended
June 30, 2001, in April 2001, the Company issued $310,000 face value Series 1
Promissory Notes. The Series 1 Promissory Notes bear interest at a rate of 10%
per annum calculated annually. The Series 1 Promissory Notes are due and payable
on or before the date the Due Date, and carry a right of set-off, which provides
that the Lenders may set-off the principal amount of the Series 1 Promissory
Notes against a subscription for shares of the Company's Common Stock at an
issue price of $2.50.

In addition, the Company granted to the Lenders, warrants to purchase an
aggregate of 155,000 shares of the Company's Common Stock at an exercise price
of $2.50 per share.

The Company believes that issuance of the Series 1 Promissory Notes and the
grants of warrants are exempt from registration under the Securities Act of
1933, as amended (the "Securities Act") and the rules and regulations
promulgated thereunder.

                                      -11-
<PAGE>

Item 6 Management's Discussion and Analysis or Plan of Operation.

                                Plan of Operation

The Company is working to have a minimum of 6 major contracts with
internationally recognized customers as soon as possible. Initial contacts have
been made with:

1. Unisys Corporation

2. Biometric Tracking

3. Siemens AG (Germany)

4. RJM Rheinmetal Jena, (Germany)

5. Lufthansa (Germany)

6. El Al Airlines

7. Bode Panzer Safes (Europe).

Bepariko will continue discussions with these and other interested companies to
complete a contract or contracts. Our Company may be offered an opportunity to
joint venture with one or more of these companies to assist in furthering our
business plans. The possibility of contracts or joint ventures vary from alien
identification ID cards, entrance to airline secured areas, corporate security
and military applications.

We will continue negotiations with major industrial companies that have
expressed a desire to incorporate the use of our patent into their operational
systems. For the right to use the patent a facilitation charge will be paid to
our company. Each time a system is accessed we will receive a use fee.

We have attended security trade shows such as Secure-Tech and Card-Tech to
introduce our product to a wide sector of the market. We will continue to
display and demonstrate our product to potential markets available at these
trade shows.

Many industrial and multi-national companies that would be interested in
applying our multi-fingerprint identification system to their existing systems
prefer to operate those systems in house. This could present an opportunity for
Bepariko to enter into a joint venture with one or more of these companies. At
this time, Bepariko has no proposal, agreement, understanding or arrangement to
enter into such a joint venture agreement with any specific business or company.

Our Company will not restrict its search for business opportunities to any
specific business, industry or geographical location. The discussion of the
proposed business under this caption and throughout this Registration Statement
is purposefully general and is not meant to be restrictive of the Company's
virtually unlimited discretion to search for and enter into potential business
opportunities.

Bepariko's potential success is heavily dependent on it's management, which will
have virtually unlimited discretion in searching for and entering into business
opportunities. The sole director and officer of our company has not had any
experience in the proposed business of the Company.

                                      -12-
<PAGE>

Bepariko may seek to develop a new product or service, or acquire an established
business which may be experiencing financial or operating difficulties and is in
the need for additional capital which is perceived to be easier to raise by a
public company. In some instances, a business opportunity may involve the joint
venture with a corporation that does not need substantial additional cash. Our
company may purchase assets and establish wholly owned subsidiaries in various
business or purchase an existing businesses as subsidiaries.

Bepariko anticipates that the selection of a business opportunity will be
complex and extremely risky. Potentially, available business opportunities may
occur in many different industries and at various stages of development. This
will make the task of comparative investigation and analysis of any
opportunities extremely difficult and complex.

As is customary in the industry, Bepariko may pay a finder's fee for locating
and executing a contract with a company to use the multi-fingerprint patent. If
any fee is paid, it will be approved by our Company's board of directors and
will be in accordance with the industry standards. Such fees are customarily
between 1% and 5% of the size of the transaction based upon a sliding scale of
the amount involved. These fees are typically in the range of 5% on a $1,000,000
transaction ratably down to 1% in a $4,000,000 transaction. Management has
adopted a policy that a finder's fee could, in certain circumstances, be paid to
any employee, officer, director or 5% shareholder of Bepariko, if this person
plays a material role in bringing a transaction to completion.

Bepariko has not formulated any policy regarding the use of consultants or
outside advisors. In the future if our Company finds it necessary to employ
consultants or outside advisors the board of directors will establish a policy
in line with policies being utilized in the industry.

Presentation of Opportunities to Bepariko BioCom.

Bepariko anticipates that business opportunities for possible contracts or joint
ventures will be referred by various sources, including its officers and
directors, professional advisers, securities broker-dealers, venture
capitalists, members of the financial community, and others who may present
unsolicited proposals.

Our Company will seek a potential business opportunity from all known sources,
but will rely principally on personal contacts of its officers and directors as
well as indirect associations between them and other business and professional
people.

Bepariko's evaluation of future business.

The sole officer and director of Bepariko is currently employed in another
position. Currently Mr. Harrington devotes approximately three hours each week
to the operations of the business. The sole officer and director will dedicate
whatever time is required for the operations and development of the Company's
business. Mr. Harrington has other interests that require portions of his time.
He currently does not have any investments or ownership in other companies that
could pose a conflict with Bepariko.

                                      -13-
<PAGE>

The analysis of new business opportunities will be undertaken by or under the
supervision of the sole officer and director of Bepariko. Management intends to
concentrate on identifying prospective business opportunities that may be
brought to its attention through present associations with management. In
analyzing prospective business opportunities, management will consider the
available technical, financial and managerial resources. Working capital and
other financial requirements will be required.

Our Company must consider the quality and experience of management potentials
for further research and development. Officers and directors of each company
will meet personally with management and key personnel of the firm sponsoring
the business opportunity as part of their investigation. To the extent possible,
Bepariko intends to utilize written reports and personal investigation to
evaluate business opportunities.

Bepariko will not restrict its search for any specific kind of business, but may
contract with a company which is in its preliminary or development stage, which
is already in operation, or in essentially any stage of its corporate life.

Bepariko may enter into other business ventures.

In implementing a structure for a particular business opportunity, Bepariko may
become a party to a joint venture, franchise or licensing agreement with another
corporation or entity. It may also purchase stock or assets of an existing
business. On the consummation of a transaction, it is possible that the present
management and shareholders of Bepariko will not be in control of the Company.
In addition, the sole officer and director of Bepariko may, as part of the terms
of the transaction, resign and be replaced by new officers and directors without
a vote of Bepariko's shareholders.

As part of our Company's investigation, the sole officer and director of
Bepariko will meet personally with management and key personnel. He may visit
and inspect material facilities, obtain independent analysis or verification of
certain information provided, check reference of management and key personnel,
and take any other reasonable investigative measures, to the extent of our
Company's limited financial resources and management expertise.

The manner in which our Company participates in an opportunity will depend on
the nature of the opportunity, the respective needs and desires of Bepariko and
other parties, the management of the opportunity, and the relative negotiating
strength of our Company and the other management.

Bepariko will not have sufficient funds to undertake any significant
development, marketing and manufacturing of any products which may be acquired.
Our Company will, in all likelihood, be required to either seek debt or equity
financing or obtain funding from third parties, Our Company would probably be
required to give up a substantial portion of its interest in any acquired
product. There is no assurance that our Company will be able either to obtain
additional financing or interest third parties in providing funding for the
further developing, marketing and manufacturing of any products acquired.

It is anticipated that the investigation of specific business opportunities and
the negotiation, drafting and execution of relevant agreements, disclosure
documents and other instruments will require substantial management time and
attention and substantial costs for accountants, attorneys and others. If a
decision were made not to participate in a specific business opportunity the
costs incurred in the related investigation would not be recoverable. Even if an
agreement is reached for the participation in a specific business opportunity,
the failure to consummate that transaction may result in the loss to our Company
of the related costs incurred.

                                      -14-
<PAGE>

Management believes that the Company may be able to benefit from the use of
"leverage" in a business opportunity. Leveraging a transaction involves the
purchase of a business through incurring significant indebtedness for a large
percentage of the purchase price for that business. Through a leveraged
transaction, the Company would be required to use less of its available funds
for purchasing the business opportunity and, therefore, could commit those funds
to the operations of the business opportunity or to other activities. The assets
of the business opportunity will ordinarily secure the borrowing involved in a
leveraged transaction.

Competition Bepariko BioCom may encounter.

Bepariko is an insignificant participant among firms, which engage in business
combinations with financing of development stage enterprises. There are many
established management and financial consulting companies and venture capital
firms which have significantly greater financial and personnel resources,
technical expertise and experience than Bepariko. In view of our Company's
limited financial resources and management availability, it will continue to be
at a significant competitive disadvantage.

Regulation and Taxation that may be applied to Bepariko BioCom.

The Investment Company Act of 1940 defines an "investment company" as an issuer,
which is or holds itself out as being engaged primarily in the business of
investing, reinvesting or trading of securities. While Bepariko does not intend
to engage in these activities, it could become subject to regulation under the
Investment Company Act of 1940 in the event Bepariko obtains or continues to
hold a minority interest in a number of development stage enterprises. Bepariko
could be expected to incur significant registration and compliance costs if
required to register under the Investment Company Act of 1940. Management will
continue to review the Company's activities from time to time with a view toward
reducing the likelihood that Bepariko could be classified as an "investment
company."

Liquidity and Capital Resources

As previously disclosed, on March 15, 2001, the Company announced that it had
entered into a definitive agreement (the "Acquisition Agreement") with the
shareholders of Global Genomics Capital, Inc. ("GGC"), a California company, to
acquire all of the issued and outstanding shares of GGC in exchange for the
issuance by the Company of approximately 9.1 million shares in its capital.
During the fourth quarter of fiscal 2001, the Company and the shareholders of
GGC terminated the Acquisition Agreement.

In April 2001, the Company entered into financing arrangements for an aggregate
of $310,000 with unrelated parties (the "Lenders") and issued Series 1
Promissory Notes (the "Series 1 Promissory Notes") to evidence such borrowings.
The Series 1 Promissory Notes bear interest at a rate of 10% per annum
calculated annually. The Series 1 Promissory Notes are due and payable on or
before the date (the "Due Date") which is the earlier of (i) September 1, 2001,
and (ii) the date that the Company completes the, acquisition of all the GGC
shares. In addition, the Company granted to the Lenders, warrants to purchase an
aggregate of 155,000 shares of the Company's Common Stock at an exercise price
of $2.50 per share. The Series 1 Promissory Notes carry a right of set-off,
which provides that the Lenders may set-off the principal amount of the Series 1
Promissory Notes against a subscription for shares of the Company's Common Stock
at an issue price of $2.50.

                                      -15-
<PAGE>

The Series 1 Promissory Notes matured on September 1, 2001, and had not been
repaid at the December 31, 2001 fiscal year end. Subsequent to December 31,
2001, the Company and the Lenders executed amendments to the Series 1 Promissory
Notes, extending the repayment date to the earlier of April 10, 2003 or the
receipt of funds or financings by the Company from any other source.

In April 2001, the Company entered into a financing arrangement with GGC,
whereby the Company advanced $250,000 to GGC and GGC issued $250,000 principal
amount of Convertible Promissory Notes (the "GGC Notes") to the Company. The GGC
Notes bear interest at a rate of 10% per annum calculated annually, and provide
that the principal amount and accrued and unpaid interest will be due and
payable on demand, by the Company, if the Company completes the acquisition of
the GGC Shares. In the event that the Acquisition Agreement is terminated for
any reason other than the default of GGC, then GGC will have the option, upon
giving notice to the Company, to convert the principal amount of the GGC Notes,
and all accrued and unpaid interest, into shares of Common Stock of GGC at a
conversion rate of $2.50 per share. If the Acquisition Agreement is terminated
as a result of default by GGC or its shareholders, the principal amount and all
accrued and unpaid interest on the GGC Notes will be due and payable on August
31, 2001.

The GGC Notes matured on August 31, 2001, and have not yet been repaid to the
Company. The Company GGC have been in discussions with respect to the extension
of the GGC Notes, and subsequent to the Company's fiscal year end, the Company
and GGC entered into an agreement whereby the Company extended the date for the
repayment of the GGC Notes and agreed to a repayment or conversion of the GGC
Notes into shares of GGC in connection with the proposed merger of GGC with a
third entity.

Events subsequent to December 31, 2001.

On January 2, 2002, Bepariko announced that it had executed a letter of intent
to acquire First Responder Group, Inc. ("First Responder"), a New York based
company involved in the provision of goods and services used to educate prepare
and protect consumers and health professionals in the area of domestic
preparedness against terrorism.

The acquisition of First Responder is subject to a number of conditions
precedent including: the completion by the Company, of due diligence and a
financing by the Company and the execution of a definitive merger agreement
between the Company and First Responder. There can be no assurance that the
acquisition of First Responder will be completed or that the Company will be
successful in completing any financing.

Our plan of operation is dependent on our ability to complete the acquisition of
First Responder or the marketing of the technology related to our patent, so
that we can generate revenues. There can be no assurances that we complete the
acquisition of First Responder or generate revenues from the marketing of the
technology associated with our patent.

If we are unable to generate revenues, then we anticipate that our expenses for
the next twelve months will be limited to the day-to-day expenditures necessary
to conduct business such as administrative expenses, which includes costs to
maintain our telephone. We have received confirmation from certain of our
shareholders and noteholders, that they will consider assisting the Company in
meeting its obligations as they arise.

                                      -16-
<PAGE>

We will need to raise additional capital to complete the acquisition of First
Responder. Such additional capital may be raised through public or private
financing as well as borrowings and other sources. We cannot guaranty that
additional funding will be available on favorable terms, if at all.

Item 7 Financial Statements.

The financial statements, the report thereon, the notes thereto and supplemental
data required by this Item 7 follow the index of financial statements appearing
at Item 13 of this Form 10K-SB, which financial statements, reports, notes, and
data are incorporated herein by reference.

Item 8 Changes In and Disagreements With Accountants on Accounting and Financial
       Disclosure.

Since the inception of Bepariko BioCom on April 2, 1997, the principal
independent accountant for the Company was Barry L. Friedman. Mr. Friedman
passed away on January 27, 2001, prior to commencing the audit for the fiscal
period ended December 31, 2000. The director of the Company at the time,
appointed Kurt D. Saliger, C.P.A. as the independent accountant of the Company.
Since the inception of the Company, the principal independent accountant for the
Company has neither resigned nor been dismissed, and there have been no
disagreements between the Company and the principal independent accountant for
the Company.

                                    PART III

Item 9 Directors, Executive Officers, Promoters and Control Persons; Compliance
       With Section 16(a) of the Exchange Act.

DIRECTORS AND EXECUTIVE OFFICERS.

The members of the board of directors of Bepariko serve until the next annual
meeting of stockholders, or until their successors have been elected. The
officers serve at the pleasure of the board of directors. Stephen P. Harrington
is the sole director and President of the Company. Mr. Harrington, age 43, has
been a director and the President of the Company since November 19, 2001. Mr.
Harrington is the President of SPH Investments, Inc., a private investment
company located in Bala Cynwyd, Pennsylvania and Wakefield, Rhode Island. Mr.
Harrington is also the President of SPH Equities, Inc. and has served as an
officer and director of several publicly held corporations, including Hercules
Development Group, Inc. and Expressions Graphics, Inc. Mr. Harrington graduated
from Yale University in 1980.

During the past five years, none of the principals of the Company was a
principal of another reporting issuer that was, during his tenure, struck from
the register of companies (or a similar authority in the issuer's jurisdiction
of incorporation if the issuer was incorporated outside of Nevada), or the
securities of which were the subject of a cease trade or suspension order for a
period of more than 30 consecutive days. Similarly, none of the principals of
the Company has, during the past ten years, been the subject of any penalties or
sanctions by a court or securities regulatory authority relating to the trading
in securities or the promotion, formation or management of a publicly traded
company or involving theft or fraud.

                                      -17-
<PAGE>

None of the principals of the Company has, during the past five years, been
declared bankrupt or made a voluntary assignment in bankruptcy or made a
proposal under bankruptcy or insolvency legislation or been subject to or
instituted any proceedings, arrangement or compromise with creditors or had a
receiver, receiver manager or trustee appointed to hold his assets.

Section 16(a) Beneficial Ownership Reporting Compliance

Section 16(a) of the Securities Exchange Act of 1934, as amended (the "Act")
requires the Company's directors and executive officers, and persons who own
beneficially more than ten percent of a registered class of the Company's equity
securities, to file with the Securities and Exchange Commission (the "SEC")
initial reports of ownership and reports of changes in ownership of common stock
and other equity securities of the Company. Officers, directors and greater than
ten percent stockholders are required by SEC regulation to furnish the Company
with copies of all Section 16(a) forms they file. Additionally, SEC regulations
require the Company to identify in its proxy statement and Annual Report on Form
10-KSB those individuals for whom one or more of these reports required under
Section 16 was not filed on a timely basis during the most recent fiscal year or
prior fiscal years.

To the Company's knowledge, based solely on review of the copies of such reports
furnished to the Company and representations that no other reports were required
during the year ended December 31, 2001, and except as disclosed elsewhere in
this document, the Company's officers, directors and greater than ten percent
beneficial owners failed to comply with all Section 16(a) filing requirements in
a timely manner.

Item 10 Executive Compensation.

No compensation is paid or anticipated by Bepariko until a contract is executed.

Directors currently receive no compensation for their duties as directors.

Item 11 Security Ownership of Certain Beneficial Owners and Management.

The following table sets forth, as of April 10, 2002, the number of the
Company's Common Shares beneficially owned by (a) owners of more than five
percent of the Company's outstanding Common Shares who are known to the Company
and (b) the directors and executive officers of the Company individually, and
the executive officers and directors of the Company as a group, and (c) the
percentage of ownership of the outstanding Common Shares represented by such
shares. The security holders listed below are deemed to be the beneficial owners
of shares of Common Shares underlying options and warrants which are exercisable
within 60 days from the above date. The sole director and officer of the Company
does not currently hold beneficially or directly, any shares of the Company's
Common Stock.

                                      -18-
<PAGE>

Unless otherwise indicated, the shareholders listed possess sole voting and
investment power with respect to the shares shown. The information appearing
below concerning persons other than officers and directors of the Company is to
the Company's best knowledge based on information obtained from the Company's
transfer agent.

<TABLE>
<CAPTION>
                          Name and Address of                Amount and Nature
Title of Class            Beneficial Owner                   of Beneficial Owner      Percent of Class
------------------------- ---------------------------------- ------------------------ --------------------------------

<S>                       <C>                                <C>                      <C>
Common                    Stephen P. Harrington              Nil                      Nil
                          c/o One Belmont Avenue,
                          Suite 417, Bala Cynwyd,
                          Pennsylvania 19004

Common                    Norton Herrick                     347,000                  6.035%
                          c/o The Herrick Co.
                          2295 Corporate Blvd NW,
                          Suite 2
                          Boca Raton, Florida  33431

Common                    Directors and officers as a        Nil                      Nil
                          group (1 person)
</TABLE>

Item 12 Certain Relationships and Related Transactions.

There have been no related transactions during the last two years, to which the
Company was or is to be a party, in which the sole director and officer had or
is to have a direct or indirect material interest.

Item 13 Exhibits and Reports on Form 8-K.

(a) EXHIBITS

Exhibit No.      Description

3.1              Articles of Incorporation*

3.2              By-Laws of Bepariko Biocom*

10.1             Power of Attorney of Tino Di Pana*

10.2             Exclusive Worldwide Licensing Agreement for the Right to
                 use German Patent Number 43 22 445 *

10.3             Form of Series 1 Promissory Notes issued in April 2001

10.4             Form of Warrant Certificate issued in connection with
                 receipt of proceeds from issuance of Series 1 Promissory
                 Notes in April 2001

10.5             Form of Amendment Agreement to Series 1 Promissory Notes
                 in April 2001

* Filed previously

                                      -19-
<PAGE>

FINANCIAL STATEMENTS

        Report of Independent Auditor, Kurt D. Saliger, C.P.A., dated February
        12, 2002

        Balance sheet as of December 31, 2001, and December 31, 2000

        Statement of Operation for the years ended December 31, 2001
        and December 31, 2000; and for the period April 2, 1997
        (inception) to December 31, 2001

        Statement of Changes in Stockholders' Equity

        Statement of Cash Flows for the years ended December 31, 2001,
        December 31, 2000; and for the period April 2, 1997
        (inception) to December 31, 2001

        Notes to Financial Statements

(b) REPORTS ON FORM 8-K

There were no current reports on Form 8-K filed during the quarter ended
December 31, 2001.



                                      -20-
<PAGE>



                                   SIGNATURES

In accordance with Section 13 or 15(d) of the Exchange Act, the registrant
caused this Report to be signed on its behalf by the undersigned, thereunto duly
authorized.


          BEPARIKO BIOCOM
-----------------------------------------------------------------------
          (Registrant)

By:      /s/ "Stephen P. Harrington"
         --------------------------------------------------------------
          Stephen P. Harrington
          President and Director*

Date:    April 12, 2002

In accordance with the Exchange Act, this Report has been signed below by the
following persons on behalf of the registrant and in the capacities and on the
dates indicated.

By:      /s/ "Stephen P. Harrington"
         --------------------------------------------------------------
         Stephen P. Harrington
         President and Director (Principal executive, financial and
         accounting officer)

Date:    April 12, 2002


                                      -21-
<PAGE>

                          INDEPENDENT AUDITOR'S REPORT

Board of Directors
Bepariko Biocom
Las Vegas, Nevada

         I have audited the accompanying balance sheets of Bepariko Biocom (a
development stage company), as of December 31, 2001 and December 31, 2000 and
the related statements of stockholders' equity for December 31, 2001 and
December 31, 2000 and statements of operations and cash flows for the two years
ended December 31, 2001 and December 31, 2000 and the period of April 2, 1997
(inception) to December 31, 2001. These financial statements are the
responsibility of the Company's management. My responsibility is to express an
opinion on these financial statements based on my audit.

         I conducted my audit in accordance with generally accepted auditing
standards. Those standards require that I plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
I believe that my audit provides a reasonable basis for my opinion.

         In my opinion, the financial statements referred to above present
fairly, in all material respects, the financial position of Bepariko Biocom as
of December 31, 2001 and December 31, 2000 and the related statements of
stockholders' equity for December 31, 2001 and December 31, 2000 and statements
of operations and cash flows for the two years ended December 31, 2001 and
December 31, 2000 and the period April 2, 1997 (inception) to December 31, 2001
in conformity with generally accepted accounting principles.

         The accompanying financial statements have been prepared assuming the
Company will continue as a going concern. As discussed in Note 5 to the
financial statements, the Company has had no operations and has no established
source of revenue. This raises substantial doubt about its ability to continue
as a going concern. Management's plan in regard to these matters are also
described in Note 5. The financial statements do not include any adjustments
that might result from the outcome of this uncertainty.



Kurt D. Salinger C.P.A.
February 12, 2002



                                     -F-1-
<PAGE>


                                 BEPARIKO BIOCOM
                          (A Development Stage Company)
                                 BALANCE SHEETS

                                     ASSETS

<TABLE>
<CAPTION>
                                                                 December 31, 2001     December 31, 2000

<S>                                                                  <C>                   <C>
CURRENT ASSETS
         Cash                                                        $      47             $       0
         Accounts Receivable                                         $ 250,000             $       0
                                                                     ---------             ---------

         TOTAL CURRENT ASSETS                                        $ 250,047             $       0
                                                                     ---------             ---------

                  TOTAL ASSETS                                       $ 250,047             $       0
                                                                     =========             =========

                      LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES
         Accounts Payable                                            $ 178,652             $   3,100
                                                                     ---------             ---------

         TOTAL CURRENT LIABILITES                                    $ 178,652             $   3,100

NOTES PAYABLE                                                        $ 318,000             $       0

STOCKHOLDERS' EQUITY
         Preferred Stock, $.001 par value authorized
         10,000,000 shares; issued and outstanding at
         Dec. 31, 2001  none                                         $       0             $       0

         Common Stock, $.001 par value authorized 100,000,000
         shares; issued and outstanding at
         Dec. 31, 2000 5,750,000 shares                                                    $   5,750
         Dec. 31, 2001 5,750,000 shares                              $   5,750

         Additional Paid In Capital                                  $  32,324             $  32,324

         Deficit Accumulated During Development Stage                ($284,679)            ($ 41,174)
                                                                     ---------             ---------

         TOTAL STOCKHOLDERS' EQUITY                                  ($246,605)            ($  3,100)
                                                                     ---------             ---------

                  TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY         $ 250,047             $       0
                                                                     =========             =========
</TABLE>

         See accompanying notes to financial statements.


                                     -F-2-
<PAGE>

                                 BEPARIKO BIOCOM
                          (A Development Stage Company)
                             STATEMENT OF OPERATIONS

<TABLE>
<CAPTION>
                                                                                     April 2, 1997
                                         Year Ended            Year Ended           (inception) to
                                       Dec. 31, 2001          Dec. 31, 2000          Dec. 31, 2001

<S>                                    <C>                   <C>                    <C>
INCOME
Revenue                                $         0             $         0             $         0
                                       -----------             -----------             -----------

TOTAL INCOME                           $         0             $         0             $         0

EXPENSES

General, Selling
and Administrative                     $   225,770             $    21,600             $   266,794

Amortization                           $         0             $         0             $       150

Interest                               $    17,735             $         0             $    17,735
                                       -----------             -----------             -----------

TOTAL EXPENSES                         $   243,505             $    21,600             $   284,679
                                       -----------             -----------             -----------

NET PROFIT (LOSS)                      ($  243,505)            ($   21,600)            ($  284,679)
                                       ===========             ===========             ===========

NET PROFIT (LOSS)
PER SHARE                              ($   0.0423)            ($   0.0038)            ($   0.0495)
                                       ===========             ===========             ===========


AVERAGE NUMBER OF SHARES
OF COMMON STOCK OUTSTANDING              5,750,000               5,750,000               5,750,000
                                       ===========             ===========             ===========
</TABLE>


         See accompanying notes to financial statements.


                                     -F-3-
<PAGE>


                                 BEPARIKO BIOCOM
                          (A Development Stage Company)
                  STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY
                                December 31, 2001

<TABLE>
<CAPTION>
                                                   Common Stock
                                                   ------------                                        (Deficit)
                                            Number                              Additional            Accumulated
                                              of                                 Paid In                 During
                                            Shares              Amount           Capital           Development Stage
                                            ------              ------           -------           -----------------
<S>                                     <C>                    <C>             <C>                  <C>
Balance,
December 31, 1998                           750,000                $750            $17,324              ($17,976)

Net Loss,
December 31, 1999                                                                                        ($1,598)
                                         ----------          ----------         ----------            ----------

Balance, Dec. 31, 1999                      750,000                $750            $17,324              ($19,574)

Issued for cash
January 21, 2000                          5,000,000              $5,000            $15,000                    $0


Net Loss,
December 31, 2000                                                                                       ($21,600)
                                         ----------          ----------         ----------            ----------

Balance,
December 31, 2000                         5,750,000              $5,750            $32,324              ($41,174)


Net Loss,
December 31, 2001                                                                                      ($243,505)
                                         ----------          ----------         ----------            ----------

Balance,
December 31, 2000                         5,750,000              $5,750            $32,324             ($284,679)
                                         ==========          ==========         ==========            ===========
</TABLE>

         See accompanying notes to financial statements.


                                     -F-4-
<PAGE>



                                 BEPARIKO BIOCOM
                          (A Development Stage Company)
                             STATEMENT OF CASH FLOWS

<TABLE>
<CAPTION>
                                                                                                        April 2, 1997
                                                           Year Ended Dec.        Year Ended Dec.      (inception) to
                                                              31, 2001               31, 2000           Dec. 31, 2001

<S>                                                        <C>                 <C>                  <C>
CASH FLOWS FROM OPERATING ACTIVITIES

Net (Loss)                                                       ($243,505)            ($21,600)           ($284,679)

Adjustment to reconcile net loss to net cash provided
by operating activities

Accounts Receivable                                              ($250,000)                   $0           ($250,000)

Accounts Payable                                                   $175,552                   $0             $171,352

Amortization                                                             $0                   $0                 $150
Officer Advances                                                         $0               $1,600               $7,300
Organization Costs                                                                                             ($150)
                                                                 ----------         -----------           -----------

Net cash used in operating activities                            ($317,953)            ($20,000)           ($356,027)

CASH FLOWS FROM
FINANCING ACTIVITIES
Issue Notes Payable                                                $318,000                   $0             $318,000
Issue Common Stock                                                       $0              $20,000              $38,074
                                                                 ----------         ------------          -----------

Net increase (decrease) in cash                                         $47                   $0                  $47

Cash, Beginning of Period                                                $0                   $0                   $0
                                                                 ----------         ------------          -----------

Cash, End of Period                                                     $47                   $0                  $47
                                                                 ==========         ============          ===========
</TABLE>

         See accompanying notes to financial statements.


                                     -F-5-
<PAGE>


                                 BEPARIKO BIOCOM
                          (A Development Stage Company)
                          NOTES TO FINANCIAL STATEMENTS
                     December 31, 2001 and December 31, 2000

NOTE 1 - ORGANIZATION AND ACCOUNTING POLICIES

         The Company was incorporated April 2, 1997 under the laws of the State
of Nevada. The Company was organized to engage in any lawful activity. The
Company currently has no operations and, in accordance with SFAS #7, is
considered a development stage company.

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

         Accounting Method
                  The Company records income and expenses on the accrual method
         of accounting.

         Estimates
                  The preparation of financial statements in conformity with
                  generally accepted accounting principles requires management
                  to make estimates and assumptions that affect the reported
                  amounts of assets and liabilities and disclosure of contingent
                  assets and liabilities at the date of the financial statements
                  and the reported amounts of revenue and expenses during the
                  reporting period. Actual results could differ from those
                  estimates.

         Cash and equivalents
                  The Company maintains a cash balance in a non-interest bearing
                  bank that currently does not exceed federally insured limits.
                  For the purpose of the statements of cash flows, all highly
                  liquid investments with the maturity of three months or less
                  are considered to be cash equivalents. There are no cash
                  equivalents December 31, 2001 or as of December 31, 2000.

         Income Taxes
                  Income taxes are provided for using the liability method of
                  accounting in accordance with Statement of Financial
                  Accounting Standards No. 109 (SFAS #109) "Accounting for
                  Income Taxes". A deferred tax asset or liability is recorded
                  for all temporary differences between financial and tax
                  reporting. Deferred tax expense (benefit) results from the net
                  change during the year of deferred tax assets and liabilities.


                                     -F-6-
<PAGE>



                                 BEPARIKO BIOCOM
                          (A Development Stage Company)
                          NOTES TO FINANCIAL STATEMENTS
                     December 31, 2001 and December 31, 2000

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

         Reporting on Costs of Start-Up Activities
                  In April 1998, the American Institute of Certified Public
                  Accountants issued Statement of position 98-5 ("SOP 98-5"),
                  "Reporting the Costs of Start-up Activities" which provides
                  guidance on the financial reporting of start-up costs and
                  organizational costs. It requires costs of start-up activities
                  and organizational costs to be expensed as incurred. SOP 98-5
                  is effective for fiscal years beginning after December 15,
                  1998 with initial adoption reported as the cumulative effect
                  of a change in accounting principle.

         Loss Per Share
                  Net loss per share is provided in accordance with Statement of
                  Financial Accounting Standards No. 128 (SFAS #128) "Earnings
                  Per Share". Basic loss per share is computed by dividing
                  losses available to common stockholders by the weighted
                  average number of common shares outstanding during the period.
                  Diluted loss per share reflects per share amounts that would
                  have resulted if dilutive common stock equivalents had been
                  converted to common stock. As of December 31, 2001 the Company
                  had no dilutive common stock equivalents such as stock
                  options.

         Year End
                  The Company has selected December 31st as its fiscal year end.

         Year 2000 Disclosure
                  The year 2000 issue had no effect on the Company.

NOTE 3 - INCOME TAXES

                  There is no provision for income taxes for the year ended
                  December 31, 2001. The Company's total deferred tax asset as
                  of December 31, 2001 is as follows:

                      Net operating loss carry forward             $284,679
                      Valuation allowance                          $284,679
                      Net deferred tax asset                             $0

                  The federal net operating loss carry forward will expire in
2017 to 2019.


                                     -F-7-
<PAGE>



                                 BEPARIKO BIOCOM
                          (A Development Stage Company)
                          NOTES TO FINANCIAL STATEMENTS
                     December 31, 2001 and December 31, 2000

NOTE 4 - STOCKHOLDERS' EQUITY

         Common Stock
                  The authorized common stock of the Company consists of
                  100,000,000 shares with a par value of $0.001 per share.

                  On July 24, 1997 the Company issued 750,000 shares of its
                  $0.001 par value common stock in consideration of $18,074 in
                  cash to its directors.

                  On January 21, 2000 the Company completed a public offering
                  that was registered with the State of Nevada pursuant to
                  N.R.S. 90.490 and was in compliance with federal registration
                  pursuant to the Form SB-2 filed with the Securities and
                  Exchange Commission being declared effective on December 22,
                  1999. Subsequently, the Company sold 5,000,000 shares of its
                  common stock at a share price of $0.004 per share for a total
                  of $20,000 cash.

         Preferred Stock
                  The authorized preferred stock of the Company consists of
                  10,000,000 shares with a par value of $0.001 per share.

NOTE 5 - GOING CONCERN

                  The Company's financial statements are prepared using general
                  accepted accounting principles applicable to a going concern
                  which contemplates the realization of assets and liquidation
                  of liabilities in the normal course of business. However, the
                  Company does not have significant cash or other material
                  assets, nor does it have an established source of revenues
                  sufficient to cover its operating costs and to allow it to
                  continue as a going concern. The Director and officer of the
                  Company and certain of the shareholders and noteholders of the
                  Company have committed to advance funds to the Company as
                  required for working capital needs.



                                     -F-8-
<PAGE>


                                 BEPARIKO BIOCOM
                          (A Development Stage Company)
                          NOTES TO FINANCIAL STATEMENTS
                     December 31, 2001 and December 31, 2000

NOTE 6 - RELATED PARTY TRANSACTIONS

                  The Company neither owns nor leases any real or personal
                  property. An officer of the Company provides office services
                  without charge. Such costs are immaterial to the financial
                  statements and accordingly, have not been reflected therein.
                  The officers and directors of the Company are involved in
                  other business opportunities. If a specific business
                  opportunity becomes available, such persons may face a
                  conflict in selecting between the Company and their other
                  business interests. The Company has not formulated a policy
                  for the resolution of such conflicts.

NOTE 7 - WARRANTS AND OPTIONS

                  There are no warrants or options outstanding to acquire any
                  additional shares of common or preferred stock.

NOTE 8 - OFFICER ADVANCES

                  While the Company was seeking additional capital to advance
                  its business plan, an officer of the Company has advanced
                  funds on behalf of the Company to pay for any costs incurred
                  by it. These funds are interest free.




                                     -F-9-
<PAGE>




EXHIBITS LIST

Exhibit No.     Description

3.1             Articles of Incorporation*

3.2             By-Laws of Bepariko Biocom*

10.1            Power of Attorney of Tino Di Pana*

10.2            Exclusive Worldwide Licensing Agreement for the Right to use
                German Patent Number 43 22 445 *

10.3            Form of Series 1 Promissory Note issued in April 2001

10.4            Form of Warrant Certificate issued in connection with receipt
                of proceeds from issuance of Series 1 Promissory Notes in
                April 2001

10.5            Form of Amendment Agreement to Series 1 Promissory Notes in
                April 2001

* Filed previously




                                     -F-10-